Updated Jul 16, 2026
Hassanein Waleed H has filed 1 SEC Form 4 filing across 1 company in the last 90 days — active on both sides. Lifetime open-market purchases: $2.98M. Lifetime open-market sales: $1.14M. Historical track record: 1/5 stars across 4 tracked purchases.

Waleed H. Hassanein is the President and CEO of TransMedics Group, Inc., a company focused on transforming organ transplant therapy. Under his leadership, the company has developed innovative technologies like the Organ Care System to improve organ preservation and transplantation outcomes.
| Role | Insider |
|---|---|
| Notability | 50/100 |
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★☆☆☆☆ (1/5) |
|---|---|
| Total purchases tracked | 4 |
| Purchases with forward-return data | 4 |
| 30-day win rate | 2500% |
| 90-day win rate | 10000% |
| Avg 5-day return | +1418.80% |
| Avg 30-day return | -574.28% |
| Avg 90-day return | +884.28% |
| Best 30-day return | +752.20% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-15 | TMDX | TransMedics Group, Inc. | A — Grant or award | 49.7K | $0.00 | |
| 2025-11-18 | TMDX | TransMedics Group, Inc. | P — Open-market purchase | 8.8K | $114.00 | $1.00M |
| 2025-08-06 | TMDX | TransMedics Group, Inc. | P — Open-market purchase | 1.9K | $116.85 | $217K |
| 2025-08-06 | TMDX | TransMedics Group, Inc. | P — Open-market purchase | 6.6K | $116.08 | $768K |
| 2025-08-06 | TMDX | TransMedics Group, Inc. | P — Open-market purchase | 8.4K | $118.68 | $997K |
| 2024-10-17 | TMDX | TransMedics Group, Inc. | S — Open-market sale [10b5-1] | 300 | $135.04 | $41K |
| 2024-10-17 | TMDX | TransMedics Group, Inc. | S — Open-market sale [10b5-1] | 1.2K | $134.23 | $161K |
| 2024-10-17 | TMDX | TransMedics Group, Inc. | S — Open-market sale [10b5-1] | 3.5K | $132.82 | $467K |
| 2024-10-17 | TMDX | TransMedics Group, Inc. | S — Open-market sale [10b5-1] | 3.6K | $131.91 | $476K |
| 2024-10-17 | TMDX | TransMedics Group, Inc. | M — Option exercise [10b5-1] | 8.6K | $13.28 | $115K |
Waleed H. Hassanein is the President and CEO of TransMedics Group, Inc., a company focused on transforming organ transplant therapy. Under his leadership, the company has developed innovative technologies like the Organ Care System to improve organ preservation and transplantation outcomes.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 4 open-market purchases ($2.98M) and 4 open-market sales ($1.14M) across all tracked filings.
Across 4 tracked purchases, Hassanein Waleed H averaged -574.3% avg 30-day return with a 2500% 30-day win rate. InsiderAlpha rates the track record at 1/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Hassanein Waleed H profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.